Dib-u-eegis Mudnaan Leh oo Lagu Sameeyay Trastuzumab Deruxtecan Shiinaha si Loogu Sameeyo Kansarka Caloosha ee Horumarsan ee HER2-Positive

Juun 10, Xarunta Qiimaynta Daawada (CDE) ee Maamulka Badeecadaha Caafimaadka Qaranka (NMPA) ayaa ku dhawaaqday in Trastuzumab Deruxtecan (T-DXd, DS-8201a) la soo jeediyay in la siiyo dib u eegis mudnaan leh oo ku saabsan daaweynta bukaanada qaangaarka ah ee qaba adenocarcinoma-ga caloosha ama caloosha ee HER2-positive ee maxalliga ah ama metastatic metastatic kuwaas oo helay hal daaweyn oo hore.

Tijaabada Wajiga II ee DESTINY-Gastric01, DS-8201 si weyn ayay u hagaajisay heerarka jawaab celinta iyo badbaadada guud ee bukaanada qaba HER2-positive gastric adenocarcinoma (GC) ama gastroesophageal junction (GEJ) adenocarcinoma. Tijaabada waxaa lagu diiwaan geliyay 125 bukaan oo lagu daaweeyay DS-8201, taasoo muujinaysa heerka jawaab celinta ujeedka ah (ORR) oo ah 51%, muddada dhexdhexaadka ah ee jawaab celinta (DOR) oo ah 11.3 bilood, iyo heerka xakamaynta cudurka (DCR) oo ah 86%.

Daraasadda Wajiga III ee DESTINY-Gastric04 waxay qiimeysay waxtarka iyo badbaadada Trastuzumab Deruxtecan (6.4 mg/kg) marka loo eego ramucirumab iyo paclitaxel oo ah daaweyn labaad oo loogu talagalay bukaanada qaba HER2-positive oo aan la kala saari karin iyo/ama caloosha oo aan la kala saari karin ama GEJ adenocarcinoma. Natiijooyinku waxay muujiyeen, laga bilaabo Oktoobar 24, 2024, kooxda trastuzumab deruxtecan waxay muujisay badbaado guud oo aad u dheer (OS) (14.7 bilood marka loo eego 11.4 bilood, HR=0.70, P=0.0044) iyo badbaado aan horumar lahayn (PFS) (6.7 bilood marka loo eego 5.6 bilood). ORR sidoo kale wuu ka sarreeyay (44.3% marka loo eego 29.1%), sidoo kale DCR (91.9% marka loo eego 75.9%).

Trastuzumab deruxtecan (oo hore loogu yaqaanay DS-8201), oo ah isku-xidhka antibody-dawada oo ka kooban antibody monoclonal ah oo ka hortagga HER2 monoclonal ah oo ku xiran culayska topoisomerase I inhibitor iyada oo loo marayo isku-xidhe la kala saari karo oo ku salaysan tetrapeptide, ayaa loo oggolaaday daaweynta bukaanada qaba kansarka naasaha ee HER2-positive ee metastatic. Si ka duwan daawaynta kale ee badan ee HER2 ee la ansixiyay, trastuzumab deruxtecan sidoo kale si wax ku ool ah ayuu u bartilmaameedsan karaa unugyada burooyinka ee muujiya heerarka hoose ee HER2 wuxuuna keeni karaa culayska cytotoxic ee xooggan (saamiga daawada-ilaa-antibody, 8:1) iyada oo loo marayo saameynta daawada ee unugyada burooyinka deriska ah ee si kala duwan u muujinaya HER2.

Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.

Lambarka Taleefanka: 4008803716

Email：myimmnet@163.com